清胰方联合参麦注射液治疗重症急性胰腺炎临床研究  

Clinical Study on Qingyi Prescription Combined with Shenmai Injection for Severe Acute Pancreatitis

作　　者：李长力[1] 郑喜胜[1] 贾明雅[1] LI Changli;ZHENG Xisheng;JIA Mingya

机构地区：[1]南阳市中心医院重症医学科,河南南阳473000

出　　处：《新中医》2022年第6期106-109,共4页New Chinese Medicine

摘　　要：目的:观察清胰方联合参麦注射液治疗重症急性胰腺炎(SAP)的临床疗效。方法:选取100例SAP患者,按照不同治疗方式分为观察组和对照组,每组50例。2组均给予常规治疗,对照组在此基础上给予参麦注射液治疗,观察组在对照组基础上加用清胰方治疗。2组均治疗2周。比较2组临床疗效、症状缓解时间;比较2组治疗前后血淀粉酶、尿淀粉酶、炎症因子水平及免疫功能。结果:观察组总有效率90.00%,高于对照组78.00%(P<0.05)。观察组腹痛缓解、肠鸣音恢复、首次排便、血淀粉酶恢复时间均短于对照组(P<0.05)。治疗后,2组血淀粉酶、尿淀粉酶水平均较治疗前降低(P<0.05),观察组血淀粉酶、尿淀粉酶水平均低于对照组(P<0.05)。治疗后,2组CD4^(+)水平及CD4^(+)/CD8^(+)值均较治疗前升高(P<0.05),CD8^(+)水平均较治疗前降低(P<0.05);观察组CD4^(+)水平及CD4^(+)/CD8^(+)值均高于对照组(P<0.05),CD8^(+)水平低于对照组(P<0.05)。治疗后,2组超敏C-反应蛋白(hs-CRP)、白细胞介素-2 (IL-2)、白细胞介素-6 (IL-6)、肿瘤坏死因子-α(TNF-α)水平均较治疗前降低(P<0.05),观察组hs-CRP、IL-2、IL-6、TNF-α水平均低于对照组(P<0.05)。结论:清胰方联合参麦注射液治疗SAP临床疗效较好,可增强患者的免疫功能,降低炎症因子水平,缓解临床症状。Objective:To observe the clinical effect of Qingyi prescription combined with Shenmai injection for severe acute pancreatitis(SAP).Methods:A total of 100 cases of SAP patients were divided into the observation group and the control group according to their different treatment methods,with 50 cases in each group.Both groups were given routine treatment,the control group was additionally treated with Shenmai injection,and the observation group was additionally treated with Qingyi prescription based on the treatment of the control group.Both groups were treated for two weeks.The clinical effects and the remission duration of symptoms in the two groups were compared.Before and after treatment,the levels of blood amylase,urine amylase,inflammatory factors and the indexes of immune function in the two groups were compared.Results:The total effective rate was 90.00%in the observation group,higher than that of 78.00%in the control group(P<0.05).The remission duration of abdominal pain,the recovery time of bowel sounds,the first defecation time and the recovery time of blood amylase in the observation group were shorter than those in the control group(P<0.05).After treatment,the levels of blood amylase and urine amylase in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of blood amylase and urine amylase in the observation group were lower than those in the control group(P<0.05).After treatment,CD4^(+)levels and CD4^(+)/CD8^(+)values in the two groups were increased when compared with those before treatment(P<0.05),and CD8^(+)levels were decreased(P<0.05);CD4^(+)level and CD4^(+)/CD8^(+)value in the observation group were higher than those in the control group(P<0.05),and CD8^(+)was lower(P<0.05).After treatment,the levels of high-sensitivity C-reactive protein(hs-CRP),interleukin-2(IL-2),interleukin-6(IL-6) and tumor necrosis factor-α(TNF-α) in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of hs-CRP,IL-2,IL-6 and TNF-αin th

关 键 词：重症急性胰腺炎 清胰方 参麦注射液 淀粉酶 免疫功能 炎症因子 

分 类 号：R576[医药卫生—消化系统]